A new article describes the ongoing INSIGHT 2 study that is assessing the effects and safety of tepotinib combined with osimertinib in patients with lung cancer that has stopped responding to osimertinib because of a type of resistance called MET amplification. The article has been published in Future Oncology and the authors have published a plain language summary alongside the article.
Read the plain language summary for free here.
